Method of modulating pcsk9 and uses thereof
OwnerChangyang ZHOU, Yidi SUN +2inventors
InventorsChangyang ZHOU, Yidi SUN, Wenbo PENG, Shaoshuai MAO
Life of this patent
Estimating the term…
Abstract
This disclosure provides CRISPR/Cas9 based fusion molecules and guide RNAs for use in in vivo targeted reduction or elimination of PCSK9 gene products. This disclosure also relates to formulations, methods of production and methods of use thereof.
Claims39
A method for
- (a) reducing or eliminating the expression of a Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) gene product in a cell comprising the step of introducing into the cell:
- a fusion molecule comprising a least one DNA binding protein and at least one modulator of gene expression, or a nucleic acid sequence encoding the fusion molecule,
- wherein the modulator of gene expression provides a modification of at least one nucleotide near the PCSK9 gene and/or within a PCSK9 regulatory element,
- thereby reducing or eliminating the expression of the PCSK9 gene product in the cell;
- or
- (b) expanding a population of cells with a reduced expression of a PCSK9 gene product comprising the steps of:
- i) introducing into a plurality of cells a fusion molecule comprising a least one DNA binding protein and at least one modulator of gene expression, or a nucleic acid sequence encoding the fusion molecule,
- wherein the modulator of gene expression provides a modification of at least one nucleotide near the PCSK9 gene and/or within a PCSK9 regulatory element,
- ii) expanding the plurality of cells to produce a plurality of modified cells that have a reduced expression of the PCSK9 gene product,
- wherein the plurality of modified cells has at least 50%, at least 60%, at least 70%, at least 80% or at least 90% reduction in the PCSK9 gene product expression relative to a cell that has not been introduced with the fusion molecule or the nucleic acid sequence, and
- wherein the cell is a liver cell:
- or
- (c) (i) treating or alleviating a symptom of a PCSK9 related disorder in a subject or (ii) reducing low density lipoprotein (LDL) cholesterol in a subject, the method comprising the step of introducing to a cell of the subject;
- a fusion molecule comprising a least one DNA binding protein and at least one modulator of gene expression, or a nucleic acid sequence encoding the fusion molecule,
- wherein the modulator of gene expression provides a modification of at least one nucleotide near the PCSK9 gene and/or within a PCSK9 regulatory element,
- thereby treating or alleviating a symptom of a PCSK9 related disorder in the subject.
-5. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A sgRNA comprising the nucleic acid sequence of any one of SEQ ID NOs:
- 27-95 or 98-108.
A pharmaceutical composition comprising a fusion molecule comprising a least one DNA binding protein and at least one modulator of gene expression, or a nucleic acid sequence encoding the fusion molecule,
- wherein the fusion molecule is targeted to a genomic region near a PCSK9 gene and/or within a PCSK9 regulatory element,
- wherein the at least one modulator of gene expression provides a modification of at least one nucleotide near the PCSK9 gene and/or within a PCSK9 regulatory element,
- wherein the at least one modulator of gene expression comprises a DNA methyltransferase (DNMT), a DNA demethylase, a histone methyltransferase, a histone demethylase, or a portion thereof, or a zinc finger protein-based transcription factor or a portion thereof, or a combination thereof, and
- wherein the at least one DNA binding protein is a Cas9, dCas9, Cpf1, a zinc finger nuclease (ZNF), a transcription activator-like effector nuclease (TALEN), a homing endonuclease, a dCas9-FokI nuclease or a MegaTal nuclease.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.